GlassScriptPhysician profile
Melissa Ann Watson
NPI 1891185948
$7,573.33
in general payments reported to CMS, 2019-2025
48 companies · $23.93 in 2025
The $23.93 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,245 · 2022: $2,146 · 2023: $1,685 · 2024: $1,474 · 2025: $23.93.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,183.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,182.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,696.55 | 2021-2024 | |
| Tris Pharma INC | $1,176.18 | 2024 | Dyanavel Xr |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $724.35 | 2021-2024 | Caplyta |
| Supernus Pharmaceuticals, INC. | $394.24 | 2021-2024 | Qelbree, Qelbree, Xyosted |
| Glaxosmithkline, LLC. | $352.93 | 2021-2023 | Trelegy Ellipta |
| Lilly USA, LLC | $352.14 | 2021-2024 | Mounjaro, Emgality, Jardiance |
| Astrazeneca Pharmaceuticals LP | $268.26 | 2021-2023 | Farxiga, Breztri, Bevespi Aerosphere |
| Sunovion Pharmaceuticals INC. | $261.92 | 2021-2022 | |
| Alkermes, INC. | $215.87 | 2022-2023 | Aristada, Lybalvi |
| Almatica Pharma LLC | $168.76 | 2022-2024 | Loreev Xr |
| Amgen INC. | $149.51 | 2021-2023 | Repatha, Otezla |
| Jazz Pharmaceuticals INC. | $145.06 | 2021-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $139.79 | 2021-2023 | Xifaxan, Trulance |
| Takeda Pharmaceuticals U.S.A., INC. | $137.66 | 2021-2022 | |
| Noven Therapeutics, LLC | $112.59 | 2021-2023 | Xelstrym, Secuado |
Show all 48 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melissa Watson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.